Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
about
Overactive bladder: strategies to ensure treatment compliance and adherencePersistence and compliance with medication management in the treatment of overactive bladderOveractive bladderPractical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder SyndromeThe efficacy and tolerability of mirabegron, a β3 adrenoceptor agonist, in patients with symptoms of overactive bladderClinical use of the β3 adrenoceptor agonist mirabegron in patients with overactive bladder syndromeClinical utility of transdermal delivery of oxybutynin gel via a metered-dose pump in the management of overactive bladderDoes fesoterodine have a role in the treatment of poorly managed patients with overactive bladder?Managing therapeutic competition in patients with heart failure, lower urinary tract symptoms and incontinenceMirabegron in overactive bladder patients: efficacy review and update on drug safetyIntegrative review on the non-invasive management of lower urinary tract symptoms in men following treatments for pelvic malignancies.Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people >65 years of age: A post hoc analysis of data from the SOFIA study.Real life persistence rate with antimuscarinic treatment in patients with idiopathic or neurogenic overactive bladder: a prospective cohort study with solifenacin.CUA guideline on adult overactive bladderCost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada.A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands.Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies.Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence.Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladderMedication adherence in the management of nocturia: challenges and solutions.Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United KingdomEfficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trialPostmenopausal overactive bladderFlavoxate in urogynecology: an old drug revisited.Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia.Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome.The efficacy of different doses of solifenacin in elderly patients after treating a urinary tract infection.The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial.Comparison of solifenacin and fesoterodine in treatment of overactive bladder.Can incontinence be cured? A systematic review of cure ratesPersistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in CanadaAdherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis.Adherence to Oral Therapy for Urgency Urinary Incontinence: Results from the Anticholinergic Versus Botox Comparison (ABC) TrialNew developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA.Anticholinergic use in children: Persistence and patterns of therapy.Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.Use of symptom-relieving drugs before and after surgery for urinary incontinence in women: a cohort study.Social, Economic, and Medical Factors Associated With Solifenacin Therapy Compliance Among Workers Who Suffer From Lower Urinary Tract Symptoms.Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life.Global perspective of treatment failures.
P2860
Q26746914-DA7D8DE6-05C6-42E4-8BD9-5888750C897BQ26765014-0AF63C30-F349-4B26-951A-DCB677434892Q26766174-6CCF7D04-5AD0-4D2A-81A8-A1093279CCE5Q26770415-86408861-6B6D-4774-8A8F-9DFD3BD8126CQ26770419-855D2FDD-B34E-426B-9FBD-9BF569C95287Q26783536-37E4B072-3231-436E-9457-EF7B1301104FQ26824182-A2B5F222-AD1D-41BE-B88D-4BA8F43CFFACQ27000698-3D50BB55-4F8C-4E7D-8301-CF2D475F72C2Q27027072-F38F2AD9-BF7A-4C68-B416-6EE979F52471Q28072230-091B39E2-F95F-4ECC-94AC-D40704288A43Q30373008-4FB68E07-B199-442F-9980-B0EBFB8AFA2DQ30794849-4956AC75-47DB-4736-83D3-D23F3B6D4490Q33560320-A990F0E3-4EB0-464C-893B-44E17B461FE7Q33665026-08A0B46D-6538-49FF-82C4-7B533985E844Q33696642-BD1BA4BD-1DBF-4377-911A-AD036AD46127Q33716568-067E68E7-6E72-4891-9FE5-D93494ACA812Q33727733-B7C14B16-F068-4524-B75B-E1113AA07F67Q34405906-C95727B1-C17B-45F8-9434-02F84294FE5CQ34538448-7CAB238E-C716-4809-8773-E3C035A48FEFQ34982181-80B6061C-B0D6-4682-BC62-BF8617987F71Q34990256-EB0F85F7-47F4-44ED-9F86-E1399B7A0EBDQ34991783-C8CD7128-1E28-4A7C-B493-48B00FFD702AQ35157329-ECF02AA8-0719-45D1-8F35-813130AFAD5EQ35495603-C6D577D2-4A8A-4B0A-B89B-A52D28E62184Q35625741-B79E6B69-6139-4EF3-8ADC-FD92CB8CC074Q35908570-CF629FCA-30CA-4CBA-B323-9B90DD672824Q36038099-E5A98978-2BAF-4E4F-ACBA-345C817380D5Q36086072-1676009E-C32C-410E-B596-4E1C6F67C781Q36210264-497DEEFB-3474-48E9-AC6B-6DF11FDDED33Q36321049-DAA2A032-95A5-4E53-ACDF-93BE23E3D26BQ36326096-D6EE70BC-1C10-409E-B676-8C98E92A326EQ36332721-FEC3B844-DB71-46B4-8722-294604EF81E8Q36386201-1E71F416-5714-40A4-85F6-763B7974AF51Q36789948-090BD73C-F823-4CCA-9A54-D3CFE5EE3CF5Q36823081-17AC4600-BEA9-4FAE-9C70-66E62C5B71D1Q37119868-A1FEA64D-BC2E-4165-BCFB-421361D8F47BQ37342424-2C805700-5AD7-4C5F-90B7-516DDCAF6486Q37373376-91854D96-2807-4BF1-B383-91C08F6F7BC9Q37390990-F21726E2-8FE0-4AA1-A93D-84B819B6EB3DQ37572765-36C93C6D-0446-4030-B852-02221914DCF4
P2860
Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Persistence with prescribed an ...... tive bladder: a UK experience.
@en
Persistence with prescribed an ...... tive bladder: a UK experience.
@nl
type
label
Persistence with prescribed an ...... tive bladder: a UK experience.
@en
Persistence with prescribed an ...... tive bladder: a UK experience.
@nl
prefLabel
Persistence with prescribed an ...... tive bladder: a UK experience.
@en
Persistence with prescribed an ...... tive bladder: a UK experience.
@nl
P2093
P2860
P1433
P1476
Persistence with prescribed an ...... tive bladder: a UK experience.
@en
P2093
Adrian Wagg
Amanda Fahey
Emad Siddiqui
Gerhard Compion
P2860
P304
P356
10.1111/J.1464-410X.2012.11023.X
P577
2012-03-12T00:00:00Z